Study on the treatment effect of capecitabine and docetaxel on anthracyclines resistant breast cancer

Abstract

Objective To study the treatment effects of capecitabine and docetaxel on anthracyclines resistant breast cancer, so as to provide the evidence for the effective treatment of the disease. Methods 100 patients with anthracyclines resistant breast cancer were treated in our hospital from January 2013 to January 2015, and they were considered as research subjects in this study.The clinical data were analyzed retrospectively.Capecitabine and docetaxel were used for treatment in the treatment group (n=51), and there were 49 cases treated with docetaxel in the control group.The indexes were observed including KPS score, the rate of survive to 1 year, TTP and MST.The treatment effects and safety were also compared in these two groups. Results (1)Before treatment, KPS scores in the treatment group and the control group were (83.6±1.6)points and (83.4±1.7)points respectively, and the difference was not statistically significant (t=0.606, P>0.05). After treatment, the KPS scores were (89.5±1.2)points and (86.4±1.6)points, which of the treatment group was significantly higher than the control group (t=10.989, P 0.05; nausea and vomiting: 11.76% vs.14.29%, χ2=0.104, P>0.05; constipation: 19.61% vs.18.37%, χ2=0.025, P>0.05; alopecia: 21.57% vs.20.41%, χ2=0.020, P>0.05; indigestion: 25.49% vs.22.45%, χ2=0.127, P>0.05; joint pain: 15.67% vs.20.41%, χ2=0.378, P>0.05). Conclusion Capecitabine and docetaxel are used in the treatment of anthracyclines resistant breast cancer, and it can delay the patients' condition and improve the survival time.Besides, it is also safe and effective.Therefore, this method is worth to promote and use in clinic. Key words: Breast neoplasms; Capecitabine; Docetaxel; Treatment effect